FDA approves new hep C treatment

November 25th, 2013

FDA approves new hep c treatmentThe US Food and Drug Administration (FDA) has  approved simeprevir, a new hep C treatment from Johnson & Johnson and Medivir.

Last month we reported that the FDA’s advisory panel had unanimously voted in favour of approving the treatment.

Data from clinical trials showed that the hep C virus could not be detected in about 8 in 10 patients after treatment with the drug.

The FDA is also expected to make an announcement before 8 December on whether to formally approve Gilead Science’s treatment sofosbuvir.

Hep C affects an estimated 3.2 million people in the US.

Photo by Rosalynn Rambles

  • Stay in touch

    Sign up to receive the best of our stories each month. We promise we won’t bombard you with emails: just one useful summary a month.

    Read our Privacy Policy

  • Our Partners
  • Prev
  • Hepatitis C: Your Treatment Guide

    Download your free eBook on hep C treatment here

    We will never sell or share your contact information. Our community’s trust comes first.


  • Connect: